Publication | Closed Access

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models

OncologyNovel TherapyStandard TherapiesMedicinePathologyHead And Neck CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCancer ResearchTumor MicroenvironmentTumor Biology